PMID- 22832278
OWN - NLM
STAT- MEDLINE
DCOM- 20130110
LR  - 20151119
IS  - 1423-0291 (Electronic)
IS  - 1015-2008 (Linking)
VI  - 80
IP  - 1
DP  - 2013
TI  - Expression profiling of breast tumors based on human epidermal growth factor 
      receptor 2 status defines migration-related genes.
PG  - 32-40
LID - 10.1159/000339431 [doi]
AB  - OBJECTIVE: Breast cancer is a heterogeneous neoplasm. Distinct subtypes of breast 
      cancer have been defined, suggesting the existence of molecular differences 
      contributing to their clinical outcomes. However, the molecular differences 
      between human epidermal growth factor receptor 2 (HER2)-positive and 
      HER2-negative breast cancer tumors remain unclear. The aim of this study was to 
      identify a gene expression profile for breast tumors based on their HER2 status. 
      METHODS: The HER2 status was determined by immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) in 54 breast tumor samples. Using 
      Affymetrix microarray data from these breast tumors, we established the 
      expression profiling of breast cancer based on HER2 IHC and FISH results. To 
      validate microarray experiment data, real-time quantitative reverse 
      transcription-PCR was performed. RESULTS: We found significant differences 
      between the HER2-positive and HER2-negative breast tumor samples, which included 
      overexpression of HER2, other genes located on 17q12 and genes functionally 
      related to migration. CONCLUSION: Our study shows the potential of integrated 
      genomic profiling to shed light on the molecular knowledge of HER2-positive 
      breast tumors.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Cuadros, M
AU  - Cuadros M
AD  - Department of Pathology, Hospital Universitario Virgen de las Nieves, Granada, 
      Spain. marta@decsai.ugr.es
FAU - Cano, C
AU  - Cano C
FAU - Lopez, F J
AU  - Lopez FJ
FAU - Lopez-Castro, R
AU  - Lopez-Castro R
FAU - Concha, A
AU  - Concha A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120724
PL  - Switzerland
TA  - Pathobiology
JT  - Pathobiology : journal of immunopathology, molecular and cellular biology
JID - 9007504
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/pathology
MH  - Carcinoma, Lobular/genetics/metabolism/pathology
MH  - Cluster Analysis
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/genetics/metabolism
MH  - Middle Aged
MH  - RNA, Messenger/genetics
MH  - RNA, Neoplasm/genetics
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - *Transcriptome
MH  - Tumor Suppressor Protein p53/genetics/metabolism
EDAT- 2012/07/27 06:00
MHDA- 2013/01/11 06:00
CRDT- 2012/07/27 06:00
PHST- 2011/11/21 00:00 [received]
PHST- 2012/05/08 00:00 [accepted]
PHST- 2012/07/27 06:00 [entrez]
PHST- 2012/07/27 06:00 [pubmed]
PHST- 2013/01/11 06:00 [medline]
AID - 000339431 [pii]
AID - 10.1159/000339431 [doi]
PST - ppublish
SO  - Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.